Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
Status:
Completed
Trial end date:
2017-07-20
Target enrollment:
Participant gender:
Summary
This was a multi-center, open-label, safety, tolerability and pharmacokinetic study of oral
treprostinil in pediatric subjects with stable PAH aged 7 to 17 years who were (1)
transitioning from parenteral Remodulin therapy; (2) transitioning from inhaled prostacyclin
therapy; or (3) not currently receiving prostacyclin therapy.